Exelixis (EXEL) Tops Q3 EPS by 5c, Revenue Misses, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Exelixis (EXEL) Tops Q3 EPS by 5c, Revenue Misses, Offers Guidance

Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021 4:05 PM EDT

- Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million -
- GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 -
- Conference Call and Webcast Today at 5:00 PM Eastern Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Exelixis continued to execute across all facets of our business in the third... More